Abstract
Seizures have been reported as an adverse effect of blinatumomab, a bispecific T-cell engager monoclonal antibody, which is mainly used for the treatment of pediatric relapsed/refractory leukemia. Here, we present the first reported case of super-refractory status epilepticus in an 11-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) while receiving blinatumomab. Our patient had a complete return to baseline despite enduring encephalopathy, refractory subclinical seizures requiring prolonged therapeutic burst suppression and MRI signal changes. This case demonstrates that super-refractory status epilepticus is a possible neurotoxic adverse effect of blinatumomab treatment, which responds well to conventional protocols for acute refractory seizures.
Plain language summary
Seizures are a known side effect of blinatumomab, a relatively new immunotherapy drug, which is mainly used for the treatment of relapsed leukemia in children. Here, we present the first reported case of seizure continuing for more than 24 h despite appropriate antiseizure treatment while also receiving blinatumomab. Despite an extended period of altered mental status, new abnormalities on imaging of the brain and a medication-induced coma to treat unrelenting seizures, our patient returned completely to his healthy brain function. This case demonstrates that seizures, which are especially difficult to treat, can be associated with blinatumomab immunotherapy for pediatric refractory B-ALL; however, standard-tiered seizure treatments can be effective.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Eur. J. Haematol. 106(4), 473–483 (2021). • Queudeville et al. in this recent retrospective analysis demonstrate the treatment potential of a blinatumomab for pediatric refractory B-ALL as an immunotherapy with growing use.
- 2. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatr. Blood Cancer 68(5), e28922 (2021).
- 3. . A review of blinatumomab, a novel immunotherapy. J. Oncol. Pharm. Pract. 22(4), 639–645 (2016). •• Newman et al. provide a comprehensive narrative review of blinatumomab and its clinical indications, proposed mechanism, and common adverse effects.
- 4. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34(36), 4381–4389 (2016).
- 5. Amgen Inc. Blinatumomab (Blincyto®) (package insert) (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf
- 6. . The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 29(2), 93–100 (2015).
- 7. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 97, 102189 (2021).
- 8. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119(26), 6226–6233 (2012).
- 9. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 80(1), 91–101 (2020).
- 10. . Treatment of established status epilepticus. J. Clin. Med. 5(5), 49 (2016).
- 11. . Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia 52, 53–56 (2011).
- 12. . Treatment of super-refractory status epilepticus: a review. Epilepsy Curr.
doi: 10.1177/1535759721999670 1535759721999670 (2021). - 13. . Quantitative assessment of cerebral atrophy during and after treatment in children with acute lymphoblastic leukemia. Invest. Radiol. 31(12), 749–754 (1996).
- 14. Recurrent status epilepticus in the setting of chimeric antigen receptor (CAR)-T cell therapy. Neurohospitalist 12(1), 74–79 (2022).
- 15. . New-onset seizures after bamlanivimab infusion. Br. J. Clin. Pharmacol.
doi:10.1111/bcp.15066 (2021). - 16. Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. Ann. Hematol. 96(1), 151–153 (2017).
- 17. . Cancer-treatment-induced neurotoxicity – focus on newer treatments. Nat. Rev. Clin. Oncol. 13(2), 92–105 (2016).
- 18. . Pediatric refractory and super-refractory status epilepticus. Seizure 68, 62–71 (2019). • Vasquez et al. summarize relevant evidence of treatments for very difficult to treat pediatric status epilepticus in this narrative review.
- 19. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J. Immunother. Cancer 8(1), e000621 (2020).
